LMLuciana Tamie Kato Morinaga

Luciana Tamie Kato Morinaga

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luciana Tamie Kato Morinaga has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Heparin therapy improving hypoxia in COVID-19 patients - a case series

    by Elnara Marcia Negri, Bruna Mamprim Piloto, Luciana Kato Morinaga, Carlos Viana Poyares Jardim, Shari Anne El-Dash Lamy, Marcelo Alves Ferreira, Elbio Antonio D’amico, Daniel Deheinzelin

    INTRODUCTION: Elevated D-dimer is a predictor of severity and mortality in COVID-19 patients and heparin use during in-hospital stay has been associated with decreased mortality. COVID-19 patient autopsies have revealed thrombi in the microvasculature, suggesting intravascular coagulation as a prominent feature of organ failure in these patients. Interestingly, in COVID-19, pulmonary compliance is preserved despite severe hypoxemia corroborating the hypothesis that perfusion mismatch may play a significant role in the development of respiratory failure. METHODS: We describe a series of 27 consecutive COVID-19 patients admitted to Sirio-Libanes Hospital in São Paulo-Brazil and treated with heparin in therapeutic doses tailored to clinical severity. RESULTS AND DISCUSSION: PaO2/FiO2 ratio increased significantly over the 72 hours following the start of anticoagulation, from 254(±90) to 325(±80), p=0.013, and 81% of the patients were discharged home within a mean time of 11.4 (±7.9) days. Most mechanically ventilated patients (67%) were extubated within 12.5(± 5.7) days. There were no bleeding complications or fatal events. Even though this uncontrolled case series does not offer absolute proof of DIC as the underlying mechanism of respiratory failure in COVID-19, patient’s positive response to tailored dose heparinization contributes to the understanding of the pathophysiological mechanism of the disease and provides valuable information for the treatment of these very sick patients while we await the results of further prospective controlled studies.


  • Open Access

    Lung Cavities in Chronic Thromboembolic Pulmonary Hypertension

    by Caio Julio Cesar dos Santos Fernandes, Ellen Pierre de Oliveira, Willian Salibe-Filho, Mario Terra-Filho, Carlos Vianna Poyares Jardim, Luciana Tamie Kato-Morinaga, Susana Hoette, Rogerio de Souza

    Chronic thromboembolic pulmonary hypertension (CTEPH) is a unique form of pulmonary hypertension (PH) that arises from obstruction of the pulmonary vessels by recanalized thromboembolic material. CTEPH has a wide range of radiologic presentations. Commonly, it presents as main pulmonary artery enlargement, peripheral vascular obstructions, bronchial artery dilations, and mosaic attenuation patterns. Nevertheless, other uncommon presentations have been described, such as lung cavities. These lesions may be solely related to chronic lung parenchyma ischemia but may also be a consequence of concomitant chronic infectious conditions. The objective of this study was to evaluate the different etiologies that cause lung cavities in CTEPH patients. A retrospective data analysis of the medical records of CTEPH patients in a single reference PH center that contained or mentioned lung cavities was conducted between 2013 and 2016. Seven CTEPH patients with lung cavities were identified. The cavities had different sizes, locations, and wall thicknesses. In two patients, the cavities were attributed to pulmonary infarction; in 5 patients, an infectious etiology was identified. Despite the possibility of being solely associated with chronic lung parenchyma ischemia, most cases of lung cavities in CTEPH patients were associated with chronic granulomatous diseases, reinforcing the need for active investigation of infectious agents in this setting.


  • Open Access

    Use of thrombolytic agents in the treatment of acute pulmonary thromboembolism: things are not as simple as you might think

    by Carlos Henrique Miranda, Caio Julio Cesar dos Santos Fernandes, Carlos Vianna Poyares Jardim, José Leonidas Alves Jr, Francisca Alexandra Gavilanes Oleas, Luciana Tamie Kato Morinaga, Rogério de Souza


  • Open Access

    Reperfusion in acute pulmonary thromboembolism

    by Caio Julio Cesar dos Santos Fernandes, Carlos Vianna Poyares Jardim, José Leonidas Alves Jr, Francisca Alexandra Gavilanes Oleas, Luciana Tamie Kato Morinaga, Rogério de Souza

    Acute pulmonary thromboembolism (APTE) is a highly prevalent condition (104-183 cases per 100,000 person-years) and is potentially fatal. Approximately 20% of patients with APTE are hypotensive, being considered at high risk of death. In such patients, immediate lung reperfusion is necessary in order to reduce right ventricular afterload and to restore hemodynamic stability. To reduce pulmonary vascular resistance in APTE and, consequently, to improve right ventricular function, lung reperfusion strategies have been developed over time and widely studied in recent years. In this review, we focus on advances in the indication and use of systemic thrombolytic agents, as well as lung reperfusion via endovascular and classical surgical approaches, in APTE.